Treatment of verbal agitation with a selective serotonin reuptake inhibitor.
The objective of this study was to examine the safety and efficacy of paroxetine as an alternative to neuroleptic medications for the treatment of verbal agitation in demented patients. An open case series design was used, and the setting included two nursing homes and an outpatient geriatric clinic. Participants were eight consecutive nursing home residents and seven community-dwelling older adults diagnosed with dementia who exhibited verbal agitation in the form of repetitive questions or unwarranted request for attention. Patients received paroxetine orally in doses of 10 mg to 40 mg per day. The Cohen-Mansfield Agitation Inventory (CMAI) was used to rate the frequency of verbal agitation. A baseline score was obtained before starting paroxetine. Six scores were then obtained at 2-week intervals over a period of 3 months. All patients had reduction (2-4 points per item) in the CMAI scores at the end of the first month of treatment with paroxetine. Scores were further reduced (up to 5 points per item, 67%-71% reduction from baseline) in five patients at the end of the third month of treatment. Most patients tolerated paroxetine well. In this report, the use of paroxetine was associated with reduction in verbal agitation. This finding supports the possibility that verbal agitation in demented patients could be a manifestation of underlying depression.
Department of Geriatric Medicine, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, USA.
F H
FH
Ramadan
B J
BJ
Naughton
A G
AG
Bassanelli
D000368:Aged; D000369:Aged, 80 and over; D003704:Dementia / Q000150:complications* / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D017374:Paroxetine / Q000494:pharmacology / Q000627:therapeutic use*; D011595:Psychomotor Agitation / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014705:Verbal Behavior / Q000187:drug effects*
D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors